Publications by authors named "P Balzarini"
Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the HIV population. Scanty data are available on the prevalence and prognostic impact of MYC rearrangements in HIV-associated LBCL. We conducted a retrospective study to evaluate the clinical effect of MYC rearrangement in HIV-associated LBCL.
View Article and Find Full Text PDFArticle Synopsis
- Mucosal Melanomas (MM) are super aggressive cancers that arise in certain skin cells, and current treatments aren't helping much for advanced cases.
- Scientists created five new cell lines (named SN-MM1-5) from patient samples to better study and understand these cancers, testing how they behave in lab experiments and in mice.
- The study found that these new cell lines showed important differences from normal cells and identified specific cancer-related features, helping researchers learn more about how to treat mucosal melanomas better.
Standardized treatment options are lacking for patients with unresectable or multifocal follicular dendritic cell sarcoma (FDCS) and disease-related mortality is as high as 20%. Applying whole-genome sequencing (WGS) in one case and whole-exome sequencing (WES) in additional twelve cases, this study adds information on the molecular landscape of FDCS, expanding knowledge on pathobiological mechanisms and identifying novel markers of potential theragnostic significance. Massive parallel sequencing showed high frequency of mutations on oncosuppressor genes, particularly in RB1, CARS and BRCA2 and unveiled alterations on homologous recombination DNA damage repair-related genes in 70% (9/13) of cases.
View Article and Find Full Text PDF